医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Simavita Receives ITAC Award for “Growing an IT Company Overseas”

2015年11月27日 PM04:30
このエントリーをはてなブックマークに追加


 

SYDNEY

Simavita Limited (TSX-V:SV)(ASX:SVA), a global leader in the digital healthcare sector, is delighted to announce that it received the “Growing an IT company Overseas” award at this week’s annual Information Technology in Aged Care (ITAC) conference. The ITAC conference is the Australian aged care industry’s pre-eminent annual event for technology solutions.

The award recognises Simavita’s program to drive penetration of its Smart Incontinence Management (SIM™) system into the global digital healthcare market.

Simavita CEO, Philippa Lewis commented, “Breaking into foreign regions with a digital healthcare platform is rare, so we are very excited that Simavita’s efforts are being recognised by our peers in the Australian digital healthcare space. We are starting to see the evidence of early stage traction from our work and this award acknowledges the momentum building offshore around SIM™ as we push hard to drive our Australian developed technology into other markets.”

For further information, see our website (www.simavita.com) or contact the persons outlined below.

About Simavita

Simavita is a digital healthcare company that has developed an innovative software platform. The first application for the platform is a world first solution for the management of urinary incontinence, with a focus on the elderly. This platform technology is an instrumented incontinence assessment application that provides evidence-based incontinence management care plans to the residential aged care market.

About SIM™

SIM™ is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM™ provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM™ is used to detect, record and report incontinence events during a compulsory or recommended assessment period in residential aged care facilities to develop an evidence-based incontinence care plan.

Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM™, please visit www.simavita.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005553/en/

CONTACT

Company
Simavita Limited
Philippa Lewis, +61 2 8405 6381
Chief
Executive Officer
Thomas Howitt, + 61 418 351 127
Chief
Financial Officer
or
Media and Investor Relations
Jane
Lowe, +61 411 117 774
jane.lowe@irdepartment.com.au

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果
  • GenePeeks Expands Distribution to India with Exclusive Agreement with CORE Diagnostics